Fennec Pharmaceuticals

FENC (NasdaqCM)

Fennec Pharmaceuticals Inc. is a U.S. commercial-stage biopharmaceutical company. Its lead product candidate, PEDMARK, is sodium thiosulfate for preventing cisplatin-induced ototoxicity in pediatric patients. The company sells through regional pediatric oncology specialists and medical science liaisons. It has collaborations with Tampa General Hospital Foundation and Norgine. Formerly Adherex Technologies, renamed in 2014; founded in 1996, based in Research Triangle Park, North Carolina.